CBA 研讨会系列：基因编辑: 机遇与挑战（3月2日）
约翰霍普金斯大学中国学生学者联合会 (JHU CSSA)
2019年 CBA 研讨会系列-3月
Genome Editing: Opportunities and Challenges
2019年3月2日, (星期六上午9:30至下午 3时)
Mudd 26 at Johns Hopkins University,
3400 N Charles St., Baltimore, MD 21218
(公众 $5.00, CBA, NIH, JHU-CSSA, ASQ509会员免费)
在本次研讨会上, 來自NIH, NCI, NIST, Johns Hopkins University, Pacbio and MIT Technology Review等世界顶级研究团队的专家将就以下话题进行讨论:
研讨会的日程将刊於 CBA 活动页面上。
|9:30 am-9:40am||开幕致辞(CBA president and CSSA President)|
|9:40 am-9:50 am||活动简介及各种通告|
驾驭基因组编辑技术来高精度的理解生物学Raj Chari, Ph.D., Director, Genome Modification Core NCI/FNLCR 25分钟
美国国立卫生研究院体细胞基因组编辑计划介绍Mary Ellen Perry, Ph.D., Program Leader, NIH 25分钟
美国国家标准技术研究所基因组编辑计划介绍Samantha Maragh, Ph.D., Leader, Genome Editing Program, NIST 25分钟
|11:05 am-11:15 am||小憩|
|11:15 am-11:40 am||检测基因组编辑产物Emily Hatas, Ph.D., Sr. Director, Business Development, PacBio 25分钟|
|11:40 am-12:10pm||上午讨论环节 (基础及转化科研机会
|12:10 pm-1:00 pm||午休
“深入首例CRISPR 婴儿—中国处于干细胞生物学和基因编辑的前沿” Antonio Regalado, Ph.D., Senior Editor, MIT Technology Review 25分钟
题目待定; Debra Mathews, Ph.D., MA, Assistant Director for Science Programs, Johns Hopkins Berman Institute of Bioethics 25 分钟
Genome Modification Core, Frederick National Lab for Cancer Research
Dr. Raj Chari obtained his bachelor’s degrees in both biochemistry and computer science at the University of British Columbia. He then went onto doing his PhD under the supervision of Dr. Wan Lam at the British Columbia Cancer Research Centre, specializing in lung cancer genomics. Subsequently, he did his postdoctoral fellowship at Harvard Medical School with Dr. George Church where he helped develop genome engineering technologies. After briefly working in industry at AbVitro and Juno Therapeutics, he is now the director of the Genome Modification Core at the Frederick National Lab for Cancer Research.
Mary Ellen Perry, Ph.D.
Since 2007, Dr. Mary Ellen Perry has been a program leader in the Office of Strategic Coordination, overseeing the development, implementation and assessment of several cutting-edge programs. Prior to joining the Office of the Director, Dr. Perry was a program director for the National Cancer Institute (NCI), where she oversaw a grant portfolio focused on research in aspects of molecular biology of particular relevance to cancer. Until 2016, Dr. Perry also maintained a laboratory at the NCI, employing genetically engineered mice to explore the relationship between development and cancer. Her background in cancer research is founded on a Ph.D. in biochemistry from the University of North Carolina and post-doctoral fellowships at Princeton University and the Imperial Cancer Research Fund, London (now part of Cancer Research, UK). For seven years, she led a cancer research laboratory at the University of Wisconsin-Madison, where she succeeded in winning two NIH grants, publishing several papers, and training five Ph.D. students, two of whom are now professors.
Samantha Maragh, Ph.D.
Genome Editing Program Leader
Dr. Samantha Maragh Leads the Genome Editing Program at the National Institute of Standards and Technology (NIST). This program has a primary focus on measurements and assay qualification to support genome editing applications with emphasis on gene therapy applications. Included in this program is the newly launched NIST Genome Editing Consortium, which is a public-private partnership to bring together government, industry and academia to address shared pre-competitive technical measurement and standards challenges within the genome editing community. Samantha also participates on representing the U.S. as a technical expert to the International Standards Organizations Technical Committee on Biotechnology (ISO TC 276). She is currently a U.S. liaison representing the interests and expertise of the U.S. on standards relating to nucleic acids measurements. Samantha received her M.S. in Biotechnology from Johns Hopkins University, and her Ph.D. in Human Genetics & Molecular Biology from the Johns Hopkins School of Medicine.
MIT Technology Review
Antonio is the senior editor for biomedicine for MIT Technology Review. He looks for stories about how technology is changing medicine and biomedical research. Before joining MIT Technology Review in July 2011, he lived in São Paulo, Brazil, where he wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2007, he was the science reporter at the Wall Street Journal. Antonio has an undergraduate degree in physics from Yale and a masters in science journalism from New York University.
Emily Hatas has been with PacBio for more than four years, most recently as the Senior Director of Business Development, leading several commercial initiatives in agricultural and human-biomedical research. Prior to this, she served as business development manager for KeyGene, a Dutch agricultural biotech company. She studied plant biology at the University of Wisconsin-Madison before continuing on to business school.